Patents by Inventor Nicholas Andrew Magnus

Nicholas Andrew Magnus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes for the preparation of selective estrogen receptor degraders
    Patent number: 11926634
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: March 12, 2024
    Assignee: Eli Lilly and Company
    Inventors: Alonso Jose Arguelles Delgado, Boris Arnoldovich Czeskis, Mai Khanh Nguyen Hawk, Douglas Patton Kjell, Yu Lu, Nicholas Andrew Magnus, David Michael Remick
  • PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
    Publication number: 20230322682
    Abstract: The present invention provides processes and key intermediates for the synthesis of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro-propane-2-yl)-1H-pyrazole-4-carboxamide:
    Type: Application
    Filed: September 9, 2021
    Publication date: October 12, 2023
    Inventors: Alonso Jose ARGUELLES DELGADO, Charles Todd EARY, Jared Wade FENNELL, Scott Alan FRANK, Nicholas Andrew MAGNUS, Elizabeth Ann MCFADDIN, Roger Ryan ROTHHAAR, Stacey Renee SPENCER, Radhe Krishan VAID
  • PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20230242545
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Application
    Filed: January 27, 2023
    Publication date: August 3, 2023
    Inventors: Alonso Jose ARGUELLES DELGADO, Boris Arnoldovich CZESKIS, Mai Khanh Nguyen HAWK, Douglas Patton KJELL, Yu LU, Nicholas Andrew MAGNUS, David Michael REMICK
  • PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 2-(2,6-DICHLOROPHENYL)-1-[(1S,3R)-3-(HYDROXYMETHYL)-5-(3-HYDROXY-3-METHYLBUTYL)-1-METHYL-3,4-DIHYDROISOQUINOLIN-2(1H)-YL]ETHENONE
    Publication number: 20220242826
    Abstract: The embodiments of the present invention provide processes and intermediates for the preparation of D1 PAM I: Formula (I).
    Type: Application
    Filed: June 11, 2020
    Publication date: August 4, 2022
    Inventors: Kevin Paul COLE, Neil John KALLMAN, Nicholas Andrew MAGNUS
  • Potentiators of glutamate receptors
    Patent number: 7598423
    Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: October 6, 2009
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
  • Potentiators Of Glutamate Receptors
    Publication number: 20080139505
    Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.
    Type: Application
    Filed: November 15, 2005
    Publication date: June 12, 2008
    Inventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
  • Process for the preparation of quinazolinones
    Patent number: 6175009
    Abstract: The present invention relates generally to an asymmetric synthesis of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones, and intermediates thereof. The target compounds are useful for the treatment of human immunodeficiency virus (HIV) as an inhibitor of reverse transcriptase.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: January 16, 2001
    Assignee: Dupont Pharmaceuticals Company
    Inventors: Pasquale Nicholas Confalone, Nicholas Andrew Magnus, Louis Storace